Charles River Laboratories International (CRL) Common Equity (2009 - 2025)

Charles River Laboratories International's Common Equity history runs 17 years deep, the most recent figure standing at $3.2 billion for Q4 2025.

• In Q4 2025, Common Equity fell 8.72% year-over-year to $3.2 billion; the TTM figure through Dec 2025 stood at $3.2 billion (down 8.72% YoY), while the FY2025 annual figure was $3.2 billion, down 8.72% from the prior year.
• Common Equity was $3.2 billion for Q4 2025 at Charles River Laboratories International, down from $3.4 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $3.8 billion in Q3 2024 to a low of $2.2 billion in Q1 2021.
• Historically, Common Equity has averaged $3.1 billion across 5 years, with a median of $3.2 billion in 2025.
• The sharpest annual moves came in 2021 and 2025: Common Equity jumped 32.25% in 2021, then declined 12.23% in 2025.
• A 5-year view of Common Equity shows it stood at $2.5 billion in 2021, then advanced by 17.41% to $3.0 billion in 2022, then climbed by 20.84% to $3.6 billion in 2023, then fell by 3.76% to $3.5 billion in 2024, then declined by 8.72% to $3.2 billion in 2025.
• The last three Common Equity figures came in at $3.2 billion (Q4 2025), $3.4 billion (Q3 2025), and $3.4 billion (Q2 2025), per Business Quant data.